Nivolumab for relapsed or refractory Hodgkin lymphoma: real-life experience


Bekoz H., Karadurmus N., Paydas S., Turker A., Toptas T., Tuglular T. F. , et al.

ANNALS OF ONCOLOGY, cilt.28, ss.2496-2502, 2017 (SCI İndekslerine Giren Dergi)

  • Cilt numarası: 28 Konu: 10
  • Basım Tarihi: 2017
  • Doi Numarası: 10.1093/annonc/mdx341
  • Dergi Adı: ANNALS OF ONCOLOGY
  • Sayfa Sayısı: ss.2496-2502

Özet

Background: Reed-Sternberg cells of classical Hodgkin's lymphoma (cHL) are characterized by genetic alterations at the 9p24.1 locus, leading to over-expression of programmed death-ligand 1 and 2. In a phase 1b study, nivolumab, a PD-1-blocking antibody, produced a high response in patients with relapsed or refractory cHL, with an acceptable safety profile.